What is the onset of action and duration of Enalaprilat (Angiotensin-Converting Enzyme inhibitor) IV in a patient with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Enalaprilat IV: Onset of Action and Duration

Enalaprilat IV has an onset of action within 15 minutes, with maximum effect occurring at 1-4 hours, and a duration of action of approximately 6 hours in most patients, though this duration is dose-related. 1

Pharmacokinetic Profile in Normal Renal Function

  • Onset begins within 15 minutes of IV administration, with blood pressure reduction typically evident by this time 1
  • Peak effect occurs between 1-4 hours after administration, representing maximal blood pressure reduction 1
  • Duration of hemodynamic effects is approximately 6 hours for recommended doses, though this is dose-dependent and may vary 1
  • The serum concentration profile is polyexponential with a prolonged terminal phase (>30 hours) representing a small fraction bound to ACE, but the effective half-life for accumulation is approximately 11 hours 1, 2

Modified Pharmacokinetics in Renal Impairment

In patients with impaired renal function (GFR ≤30 mL/min), the pharmacokinetics are significantly altered:

  • Peak and trough enalaprilat levels increase substantially when creatinine clearance falls below 30 mL/min 1
  • Time to peak concentration is prolonged in renal insufficiency 1
  • Time to steady-state may be delayed compared to patients with normal renal function 1
  • The effective half-life is prolonged at this level of renal impairment, necessitating dosage adjustment 1
  • More than 90% of enalaprilat is excreted unchanged in urine within 24 hours in normal renal function, making renal impairment particularly impactful 1

Clinical Implications for Dosing

For patients with renal impairment, dose reduction is mandatory:

  • The FDA label specifies that dosage adjustments are required when GFR ≤30 mL/min to prevent drug accumulation 1
  • Research supports that 0.625 mg is an appropriate initial dose for hypertensive crisis, as higher doses (1.25 mg, 2.5 mg, 5 mg) do not improve response rates or magnitude of blood pressure reduction 3
  • In patients with severe renal insufficiency, higher serum concentrations and delayed urinary excretion occur, increasing risk of prolonged hypotension 2

Practical Monitoring Considerations

  • Blood pressure should be monitored frequently after administration, particularly in volume-depleted patients who are at risk for symptomatic hypotension 1
  • The onset within 15 minutes allows for relatively rapid assessment of initial response 1, 4
  • Enalaprilat is dialyzable at 62 mL/min, which may be relevant for management of excessive hypotension in dialysis patients 1

Important Caveats

  • Abrupt withdrawal has not been associated with rapid blood pressure rebound, providing some safety margin 1
  • Symptomatic postural hypotension is infrequent but should be anticipated in volume-depleted patients 1
  • In renal impairment, the prolonged effective half-life means effects may persist longer than the typical 6-hour duration, requiring extended monitoring 1
  • Baseline renal function assessment is essential before administration, particularly checking serum creatinine and calculating GFR 5

Related Questions

What is the initial dose of enalaprilat (Angiotensin-Converting Enzyme (ACE) inhibitor) intravenously (IV) for a patient with Congestive Heart Failure (CHF) and hypertensive crisis?
What is the recommended intravenous dosing and monitoring of enalaprilat for a hypertensive emergency?
What is the proper administration and dosing of Enalapril (Angiotensin-Converting Enzyme Inhibitor)?
Should I stop taking enalapril (ACE inhibitor) because I have lower‑leg swelling and mild shortness of breath after my recent dose?
Is it safe to give intravenous enalapril (Vasotec) after administering clonidine 0.3 µg/kg when the blood pressure is 110/59 mm Hg?
How to manage post-procedural trismus (lock jaw) in a patient after a dental procedure, considering potential underlying conditions such as temporomandibular joint disorders?
What muscles should be sampled during electromyography (EMG) for suspected L3, L4, L5, and S1 radiculopathy?
Can a critically ill patient from the Intensive Care Unit (ICU) undergo a Magnetic Resonance Imaging (MRI) scan?
What is the concern with a patient having a high Mean Corpuscular Volume (MCV) and high hemoglobin levels while taking vitamin B complex with folic acid and ferrous sulfate?
What is the best course of action for a patient with normal lab values and successful transition to oral intake after IV fluids, to prevent dehydration and manage nocturnal vomiting?
What are the recommendations for using Coenzyme Q10 (CoQ10) in a patient with End-Stage Renal Disease (ESRD) on dialysis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.